Expression of p53 in renal carcinoma cells is independent of pVHL

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 578, Issue 1-2, 2005, Pages 23-32

  Stickle, Natalie H ^a   Cheng, Lynn S ^b   Watson, Ian R ^a,b   Alon, Noa ^b   Malkin, David ^a,b   Irwin, Meredith S ^a,b   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

p53; Renal cell carcinoma; VHL

Indexed keywords

HUR PROTEIN; MESSENGER RNA; PROTEIN P21; PROTEIN P53; RNA; STRUCTURAL PROTEIN; VON HIPPEL LINDAU PROTEIN;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL TRANSFORMATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPITHELIUM CELL; FAMILIAL DISEASE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REPORTER GENE; RNA STABILITY; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; UPREGULATION; VON HIPPEL LINDAU DISEASE; WILD TYPE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 25844468231     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2005.02.016     Document Type: Article

References (34)

1. M. Ohh, and W.G. Kaelin Jr. VHL and kidney cancer Meth. Mol. Biol. 222 2003 167 183
2. 2 sensing Science 292 2001 464 468
3. 2-regulated prolyl hydroxylation Science 292 2001 468 472
4. M. Ivan, T. Haberberger, D.C. Gervasi, K.S. Michelson, V. Gunzler, K. Kondo, H. Yang, I. Sorokina, R.C. Conaway, J.W. Conaway, and W.G. Kaelin Jr. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor Proc. Natl. Acad. Sci. U.S.A. 99 2002 13459 13464
5. A.C. Epstein, J.M. Gleadle, L.A. McNeill, K.S. Hewitson, J. O'Rourke, D.R. Mole, M. Mukherji, E. Metzen, M.I. Wilson, A. Dhanda, Y.M. Tian, N. Masson, D.L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P.H. Maxwell, C.W. Pugh, C.J. Schofield, and P.J. Ratcliffe C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 2001 43 54 (see comments)
6. M.A. Maynard, and M. Ohh von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer Am. J. Nephrol. 24 2004 1 13
7. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer statistics CA Cancer J. Clin. 53 2003 5 26
8. W.M. Linehan, M.M. Walther, and B. Zbar The genetic basis of cancer of the kidney J. Urol. 170 2003 2163 2172
9. S.W. Lowe Cancer therapy and p53 Curr. Opin. Oncol. 7 1995 547 553
10. S.W. Lowe, S. Bodis, A. McClatchey, L. Remington, H.E. Ruley, D.E. Fisher, D.E. Housman, and T. Jacks p53 status and the efficacy of cancer therapy in vivo Science 266 1994 807 810
11. R.R. Wallace-Brodeur, and S.W. Lowe Clinical implications of p53 mutations Cell. Mol. Life Sci. 55 1999 64 75
12. R.M. Tomasino, V. Morello, V. Tralongo, C. Nagar, R. Nuara, E. Daniele, M. Curti, and F. Orestano p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization Pathologica 86 1994 227 233
13. K.V. Gurova, J.E. Hill, O.V. Razorenova, P.M. Chumakov, and A.V. Gudkov p53 pathway in renal cell carcinoma is repressed by a dominant mechanism Cancer Res. 64 2004 1951 1958
14. S. Galban, J.L. Martindale, K. Mazan-Mamczarz, I. Lopez de Silanes, J. Fan, W. Wang, J. Decker, and M. Gorospe Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells Mol. Cell Biol. 23 2003 7083 7095
15. K. Mazan-Mamczarz, S. Galban, I. Lopez de Silanes, J.L. Martindale, U. Atasoy, J.D. Keene, and M. Gorospe RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation Proc. Natl. Acad. Sci. U.S.A. 100 2003 8354 8359
16. A. Kibel, O. Iliopoulos, J.D. DeCaprio, and W.G. Kaelin Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C Science 269 1995 1444 1446
17. K.M. Lonergan, O. Iliopoulos, M. Ohh, T. Kamura, R.C. Conaway, J.W. Conaway, and W.G. Kaelin Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2 Mol. Cell Biol. 18 1998 732 741
18. M.C. Marin, C.A. Jost, L.A. Brooks, M.S. Irwin, J. O'Nions, J.A. Tidy, N. James, J.M. McGregor, C.A. Harwood, I.G. Yulug, K.H. Vousden, M.J. Allday, B. Gusterson, S. Ikawa, P.W. Hinds, T. Crook, and W.G. Kaelin Jr. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour Nat. Genet. 25 2000 47 54
19. M. Ohh, R.L. Yauch, K.M. Lonergan, J.M. Whaley, A.O. Stemmer-Rachamimov, D.N. Louis, B.J. Gavin, N. Kley, W.G. Kaelin, O. Iliopoulos, and W.G. Kaelin The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol. Cell 1 1998 959 968
20. O. Iliopoulos, A. Kibel, S. Gray, and W.G. Kaelin Tumor suppression by the human von Hippel-Lindau gene product Nat. Med. 1 1995 822 826
21. C. Blankenship, J. Naglich, J. Whaley, B. Seizinger, and N. Kley Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity Oncogene 18 1999 1529 1535
22. K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, and W.G. Kaelin Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 2002 237 246
23. A. Schoenfeld, E.J. Davidowitz, and R.D. Burk A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor Proc. Natl. Acad. Sci. U.S.A. 95 1998 8817 8822
24. N.H. Stickle, J. Chung, J.M. Klco, R.P. Hill, W.G.J. Kaelin, and M. Ohh pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development Mol. Cell Biol. 24 2004 3251 3261
25. Z. Liu, M. Hergenhahn, H.H. Schmeiser, G.N. Wogan, A. Hong, and M. Hollstein Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene Proc. Natl. Acad. Sci. U.S.A. 101 2004 2963 2968
26. S.P. Hussain, P. Amstad, K. Raja, M. Sawyer, L. Hofseth, P.G. Shields, A. Hewer, D.H. Phillips, D. Ryberg, A. Haugen, and C.C. Harris Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung Cancer Res. 61 2001 6350 6355
27. A.C. Souici, J. Mirkovitch, P. Hausel, L.K. Keefer, and E. Felley-Bosco Transition mutation in codon 248 of the p53 tumor suppressor gene induced by reactive oxygen species and a nitric oxide-releasing compound Carcinogenesis 21 2000 281 287
28. W.G. An, M. Kanekal, M.C. Simon, E. Maltepe, M.V. Blagosklonny, and L.M. Neckers Stabilization of wild-type p53 by hypoxia-inducible factor-1 alpha Nature 392 1998 405 408
29. D. Chen, M. Li, J. Luo, and W. Gu Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function J. Biol. Chem. 278 2003 13595 13598
30. L.O. Hansson, A. Friedler, S. Freund, S. Rudiger, and A.R. Fersht Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53 Proc. Natl. Acad. Sci. U.S.A. 99 2002 10305 10309
31. M. Ohh, C.W. Park, M. Ivan, M.A. Hoffman, T.-Y. Kim, L.E. Huang, V. Chau, and W.G. Kaelin Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein beta domain Nat. Cell Biol. 2 2000 423 427
32. M. Cockman, N. Masson, D. Mole, P. Jaakkola, G. Chang, S. Clifford, E. Maher, C. Pugh, P. Ratcliffe, and P. Maxwell Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J. Biol. Chem. 275 2000 25733 25741
33. T. Kamura, S. Sato, K. Iwain, M. Czyzyk-Krzeska, R.C. Conaway, and J.W. Conaway Activation of HIF1a Ubiquitination by a reconstituted von Hippel-Lindau tumor suppressor complex Proc. Natl. Acad. Sci. U.S.A. 97 2000 10430 10435
34. N. Masson, C. Willam, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation EMBO J. 20 2001 5197 5206